Retrospective Study Based on Somatic Mutations and Genetic Polymorphisms Related to Individual Variations of Drug Effect and Adverse Drug Reaction of EGFR-TKIs,Gefitinib and Erlotinib in Non-small Cell Lung Cancer Treatment.
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 08 Aug 2017 Planned End Date changed from 1 Sep 2016 to 1 Oct 2018.
- 08 Aug 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2018.
- 03 Dec 2013 New trial record